Neuropsychiatric symptoms (NPS) associated with Alzheimer’s disease (AD), such as psychosis and agitation, affect up to 50% of individuals with AD yet remain underdiagnosed and undertreated in clinical practice. These symptoms accelerate cognitive decline, increase mortality risk, and substantially worsen patient and caregiver quality of life. Our symposium will provide a practical and engaging discussion of the underlying pathophysiology of NPS associated with AD, the limitations of off-label antipsychotic use, and emerging therapeutic agents targeting NPS associated with AD.
advertisement
Advances in the Treatment of Neuropsychiatric Symptoms of Alzheimer's Disease: Early Recognition, Diagnosis, and Innovative Emerging Therapies
Join us to learn about the diagnosis of NPS associated with Alzheimer’s disease, as well as current and emerging agents for treatment.
Live
Meeting
Information
July 30, 2025
06:15 AM - 07:45 AM EDT
Westin Harbour Castle
1 Harbour Square, Room: Frontenac Ballroom, Toronto, Canada
Share
Share
Share
Share this program on:
Details
Presenters
Commercial Support
This activity is supported by an independent educational grant from Bristol Myers Squibb.
Program Schedule*
*Subject to change
6:15am – 6:45am: Registration and Breakfast6:45am – 6:50am: Welcome and Introductions
6:50am – 7:00am: Chapter 1 - Improving Diagnostic Accuracy: Identifying NPS due to AD
7:00am – 7:10am: Chapter 2 - Risk Versus Relief: Evaluating Off-Label Antipsychotic
7:10am – 7:20am: Chapter 3 - Beyond Dopamine: The Pathophysiologic Drivers of Neuropsychiatric Symptoms
7:20am – 7:30am: Chapter 4 - Translating Science into Care: Investigational Drugs for NPS
7:30am – 7:45am: Summary and Audience Q&A
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Chair:
Marwan Sabbagh, MD, FAAN
Behavioral Neurologist
Alzheimer’s and Memory Disorders
Barrow Neurological Institute
Phoenix, AZ, USA
Dr. Sabbagh has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: AbbVie, Anavex, Cognito Therapeutics, Eisai, GSK, KeifeRx, Lilly, NeuroTherapia, Novo Nordisk, Prothena, Roche-Genentech, Signant Health, Synaptogenix
Stock/Shareholder: Alzheon, Athira, Lighthouse Pharmaceuticals, NeuroReserve, NeuroTau, Optimal Cognitive Health Company, Reservoir Neuroscience, Seq BioMarque, TransDermix, uMethod Health, Versanum
Faculty:
Alireza Atri, MD, PhD
Director, Banner Sun Health Research Institute
Lecturer on Neurology
Brigham and Women’s Hospital
Sun City, AZ, USA
Dr. Atri has no relevant relationships to disclose.
Christoph U. Correll, MD
Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell
Hempstead, NY, USA
Professor of Child and Adolescent Psychiatry at Charite University Medicine
Berlin, Berlin, GER
Dr. Correll has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: AbbVie, Alkermes, Allergan, Angelini, Aristo, Autobahn, Boehringer Ingelheim, Bristol Myers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnytsia, Delpor, Denovo, Draig, Eli Lilly, EuMentis Therapeutics, Gedeon Richter, GH, Hikma, Holmusk, Intra-Cellular Therapies, Jamjoom Pharma, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MapLight, Medincell, MedLink, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neumora Therapeutics, Neuraxpharm, Neurelis, Neurocrine, NeuShen, Newron, Noven, Novo Nordisk, Orion Pharma, Otsuka, PPD Biotech, Recordati, Relmada, Response Pharmaceutical, Reviva, Rovi, Saladax, Sanofi, Seqirus, Servier, Sumitomo Pharma America, Sun Pharma, Sunovion, Supernus, Tabuk, Takeda, Terran, Teva, Tolmar, Vertex, Viatris, Xenon
Royalties: UpToDate
Research: Boehringer Ingelheim, Janssen, Takeda
Stock/Shareholder: Cardio Diagnostics, Küleon Biosciences, LB Pharma, MedLink Global, Mindpax, Quantic, TerranReviewers/Content Planners/Authors:
- Cindy Davidson has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
- Rosanne Strauss, PharmD, has no relevant relationships to disclose.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Identify the clinical features of neuropsychiatric symptoms (NPS) associated with Alzheimer's disease (AD) to improve early recognition and diagnostic accuracy in clinical settings
- Evaluate the clinical risks and therapeutic benefits of off-label antipsychotic use in the treatment of NPS
- Explain the underlying pathophysiology of NPS associated with AD
- Evaluate available evidence from clinical trials supporting the safety and efficacy of emerging therapeutic agents targeting NPS associated with AD
Target Audience
This activity has been designed to meet the educational needs of neurologists and psychiatrists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with neuropsychiatric symptoms associated with Alzheimer’s disease.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour(s)/0.1 CEUs of pharmacy contact hour(s).
The Universal Activity Number for this program is JA0006235-0000-25-072-L01-P. This learning activity is application-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit(s). PAs should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of TotalCME you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.ADA Statement
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.
Details
Presenters
Overview
Neuropsychiatric symptoms (NPS) associated with Alzheimer’s disease (AD), such as psychosis and agitation, affect up to 50% of individuals with AD yet remain underdiagnosed and undertreated in clinical practice. These symptoms accelerate cognitive decline, increase mortality risk, and substantially worsen patient and caregiver quality of life. Our symposium will provide a practical and engaging discussion of the underlying pathophysiology of NPS associated with AD, the limitations of off-label antipsychotic use, and emerging therapeutic agents targeting NPS associated with AD.
Commercial Support
This activity is supported by an independent educational grant from Bristol Myers Squibb.
Program Schedule*
*Subject to change
6:15am – 6:45am: Registration and Breakfast6:45am – 6:50am: Welcome and Introductions
6:50am – 7:00am: Chapter 1 - Improving Diagnostic Accuracy: Identifying NPS due to AD
7:00am – 7:10am: Chapter 2 - Risk Versus Relief: Evaluating Off-Label Antipsychotic
7:10am – 7:20am: Chapter 3 - Beyond Dopamine: The Pathophysiologic Drivers of Neuropsychiatric Symptoms
7:20am – 7:30am: Chapter 4 - Translating Science into Care: Investigational Drugs for NPS
7:30am – 7:45am: Summary and Audience Q&A
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Chair:
Marwan Sabbagh, MD, FAAN
Behavioral Neurologist
Alzheimer’s and Memory Disorders
Barrow Neurological Institute
Phoenix, AZ, USA
Dr. Sabbagh has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: AbbVie, Anavex, Cognito Therapeutics, Eisai, GSK, KeifeRx, Lilly, NeuroTherapia, Novo Nordisk, Prothena, Roche-Genentech, Signant Health, Synaptogenix
Stock/Shareholder: Alzheon, Athira, Lighthouse Pharmaceuticals, NeuroReserve, NeuroTau, Optimal Cognitive Health Company, Reservoir Neuroscience, Seq BioMarque, TransDermix, uMethod Health, Versanum
Faculty:
Alireza Atri, MD, PhD
Director, Banner Sun Health Research Institute
Lecturer on Neurology
Brigham and Women’s Hospital
Sun City, AZ, USA
Dr. Atri has no relevant relationships to disclose.
Christoph U. Correll, MD
Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell
Hempstead, NY, USA
Professor of Child and Adolescent Psychiatry at Charite University Medicine
Berlin, Berlin, GER
Dr. Correll has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: AbbVie, Alkermes, Allergan, Angelini, Aristo, Autobahn, Boehringer Ingelheim, Bristol Myers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnytsia, Delpor, Denovo, Draig, Eli Lilly, EuMentis Therapeutics, Gedeon Richter, GH, Hikma, Holmusk, Intra-Cellular Therapies, Jamjoom Pharma, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MapLight, Medincell, MedLink, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neumora Therapeutics, Neuraxpharm, Neurelis, Neurocrine, NeuShen, Newron, Noven, Novo Nordisk, Orion Pharma, Otsuka, PPD Biotech, Recordati, Relmada, Response Pharmaceutical, Reviva, Rovi, Saladax, Sanofi, Seqirus, Servier, Sumitomo Pharma America, Sun Pharma, Sunovion, Supernus, Tabuk, Takeda, Terran, Teva, Tolmar, Vertex, Viatris, Xenon
Royalties: UpToDate
Research: Boehringer Ingelheim, Janssen, Takeda
Stock/Shareholder: Cardio Diagnostics, Küleon Biosciences, LB Pharma, MedLink Global, Mindpax, Quantic, TerranReviewers/Content Planners/Authors:
- Cindy Davidson has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
- Rosanne Strauss, PharmD, has no relevant relationships to disclose.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Identify the clinical features of neuropsychiatric symptoms (NPS) associated with Alzheimer's disease (AD) to improve early recognition and diagnostic accuracy in clinical settings
- Evaluate the clinical risks and therapeutic benefits of off-label antipsychotic use in the treatment of NPS
- Explain the underlying pathophysiology of NPS associated with AD
- Evaluate available evidence from clinical trials supporting the safety and efficacy of emerging therapeutic agents targeting NPS associated with AD
Target Audience
This activity has been designed to meet the educational needs of neurologists and psychiatrists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with neuropsychiatric symptoms associated with Alzheimer’s disease.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour(s)/0.1 CEUs of pharmacy contact hour(s).
The Universal Activity Number for this program is JA0006235-0000-25-072-L01-P. This learning activity is application-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit(s). PAs should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of TotalCME you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.ADA Statement
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.
Recommended
ICI Combination Regimens for First-Line Treatment of Metastatic ESCC
ICI Combination Regimens for First-Line Treatment of Metastatic ESCC
MinuteCE®ICI Combination Regimens for First-Line Treatment of Metastatic ESCC
0.75 program credits
Harry Yoon, MD
Jaffer Ajani, MD
0.75 program creditsHarry Yoon, MD
Jaffer Ajani, MD
0.75 credits 7 episodesDistinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
MinuteCE®Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
0.75 program creditsJaffer Ajani, MD
0.75 program creditsThe Impact of First-Line Treatment on Subsequent Treatment Options for Metastatic ESCC
The Impact of First-Line Treatment on Subsequent Treatment Options for Metastatic ESCC
MinuteCE®The Impact of First-Line Treatment on Subsequent Treatment Options for Metastatic ESCC
0.75 program creditsHarry Yoon, MD
Jaffer Ajani, MD
0.75 program credits